PR Newswire BiotechnologyQwen · 实盘不做把握 3/10不做原因:无增量信息
北京时间·🕒 发布 14:00:00·⟳ 抓取 14:00:19 +19s·⚡ 决策 08-31 22:09:26 +8h09m·57.1 天前
BioMarin与Ascendis就Yuviwel全球专利纠纷达成和解，Ascendis将支付美国20%/欧盟巴西韩国18%净销售额提成至2030年5月
同一具体催化（BioMarin-Ascendis Yuviwel全球和解，20%/18%提成条款）今日已通过不同源被处理4次且均为AVOID，本条无新增金额、指引修正或监管进展等关键信息。此外，提成收入相对BMRN市值占比极小（<0.15%），不构成短线可交易催化；对ASND净效应不明确（移除ITC风险为正面，但18-20%提成为负面）。
📄 原文PR Newswire Biotechnology↗ 原文
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 20…
不做 BioMarin Pharmaceutical（BMRN.US）
同一事件今日已被处理4次均AVOID，无新增事实。提成收入（早期约$10-20M/年）相对BMRN约$15-20B市值占比<0.15%，不构成短线可交易催化；且无法获取实时行情验证价格反应。
不做 Ascendis Pharma（ASND.US）
和解对ASND净效应不明确：移除ITC禁令和全球诉讼风险为正面，但18-20%提成侵蚀最新产品利润率为负面；且同一事件已被同日多次处理，无新增信息支持独立判断。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BioMarin与Ascendis就Yuviwel专利纠纷达成全球和解，Ascendis支付美国20%/其他市场18%净销售额提成至2030年5月。该事件今日已被同系统从不同源处理4次均判AVOID。量级分析：Yuviwel于2026年Q2刚商业化，早期年销售额估计$50-100M，20%提成=$10-20M/年，相对BMRN约$15-20B市值仅占0.05-0.15%，不构成短线催化。对ASND而言，移除ITC禁令风险是正面但18-20%提成侵蚀利润率是负面，净效应不明确。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 medium · price-in 风险 medium ↗
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-03-06 · 影响 invalidates
Yuviwel刚商业化数月，即使乐观估计年销售$100M，20%提成=$20M/年，相对BMRN约$15-20B市值仅占0.1-0.13%，远不足以构成短线催化
检索:BioMarin Yuviwel royalty materiality market cap
先例如何影响了这次决策
对本次决策的影响:先例不足不改变本次AVOID结论，因为事件本身已被同日多次处理且materiality不足
方向:无法建立有效先例面板
涨幅量级:先例不足，无法校准幅度
形态:无
工具执行结果 · 成功 5 · 降级 2 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,453 ms
{"result": "search_processed_events:agent query=`biomarin ascendis pharma settlement royalty yuviwel | biomarin itc section 337 yuviwel | bmrn asnd patent settlement cnp`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、1229 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - fetch_decision_experience 成功 stock_tools HTTP · 677 ms
{ - stock_quote 降级 stock_tools HTTP · 2,526 ms
取价失败: Futu returned no quote - stock_quote 降级 stock_tools HTTP · 3,774 ms
取价失败: Futu returned no quote - kb_search 成功 stock_tools HTTP · 4,366 ms
{ - search_case_library 成功 stock_tools HTTP · 31 ms
{"result": "search_case_library「BMRN.US」—— 与这些标的相关的自家决策案例(本页 12 条,该标的全历史相关记录共 21 条；ENTER 只按该标的自己的腿统计):\n◆ BMRN.US：相关历史决策 21 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 12 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-08-31 UTC 不做 · 事件:BioMarin与Ascendis - kb_fetch_document 成功 stock_tools HTTP · 33 ms
{
原文全文
展开原文 · 4,608 字
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis
SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis's Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea until May 2030.
"This outcome incentivizes companies like BioMarin to keep investing in the kind of long-term innovation that is critical to bringing breakthrough treatments to the people who need them," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "We have spent decades focused on understanding the underlying biology of rare genetic conditions, building the deep scientific expertise that led to our development of six first-in-disease medicines for patients. We look forward to continuing to innovate, bringing forward the next generation of medicines for people with serious genetic conditions, and building on our ongoing momentum for children with achondroplasia."
The scope of the settlement includes a license for BioMarin's patents that relate to Yuviwel for all current and potential indications, including achondroplasia and hypochondroplasia. It also covers the use of Yuviwel in combination with other medicines. Under the terms of the agreement, BioMarin will dismiss the pending Section 337 investigation before the ITC and the parties will resolve all claims relating to the asserted intellectual property, including litigation pending in Brazil, Denmark, Germany, South Korea and the Northern District of California.
Reaching this agreement recognizes the value of BioMarin's pioneering innovations in C-type natriuretic peptide (CNP) technology, including the development of VOXZOGO® (vosoritide), while providing a framework that enables continued access to medicine for children with achondroplasia around the world.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Forward-Looking Statements
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including without limitation, statements about: the settlement and license agreement with Ascendis Pharma A/S, including expected benefits of such agreement and anticipated royalty payments, and future commercialization of licensed products and BioMarin's expectations to continue to innovate, bringing forward the next generation of medicines for people with serious genetic conditions, and building on its momentum for children with achondroplasia. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin's ability to enforce the agreement; actual sales of licensed products; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin® and VOXZOGO® are registered trademarks of BioMarin Pharmaceutical Inc.
Contacts: |
|
Investors |
Media |
Traci McCarty |
Andrew Villani |
BioMarin Pharmaceutical Inc. |
BioMarin Pharmaceutical Inc. |
(415) 455-7558 |
(628) 269-7393 |
SOURCE BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis's Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea until May 2030.
"This outcome incentivizes companies like BioMarin to keep investing in the kind of long-term innovation that is critical to bringing breakthrough treatments to the people who need them," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "We have spent decades focused on understanding the underlying biology of rare genetic conditions, building the deep scientific expertise that led to our development of six first-in-disease medicines for patients. We look forward to continuing to innovate, bringing forward the next generation of medicines for people with serious genetic conditions, and building on our ongoing momentum for children with achondroplasia."
The scope of the settlement includes a license for BioMarin's patents that relate to Yuviwel for all current and potential indications, including achondroplasia and hypochondroplasia. It also covers the use of Yuviwel in combination with other medicines. Under the terms of the agreement, BioMarin will dismiss the pending Section 337 investigation before the ITC and the parties will resolve all claims relating to the asserted intellectual property, including litigation pending in Brazil, Denmark, Germany, South Korea and the Northern District of California.
Reaching this agreement recognizes the value of BioMarin's pioneering innovations in C-type natriuretic peptide (CNP) technology, including the development of VOXZOGO® (vosoritide), while providing a framework that enables continued access to medicine for children with achondroplasia around the world.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Forward-Looking Statements
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including without limitation, statements about: the settlement and license agreement with Ascendis Pharma A/S, including expected benefits of such agreement and anticipated royalty payments, and future commercialization of licensed products and BioMarin's expectations to continue to innovate, bringing forward the next generation of medicines for people with serious genetic conditions, and building on its momentum for children with achondroplasia. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin's ability to enforce the agreement; actual sales of licensed products; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin® and VOXZOGO® are registered trademarks of BioMarin Pharmaceutical Inc.
Contacts: |
|
Investors |
Media |
Traci McCarty |
Andrew Villani |
BioMarin Pharmaceutical Inc. |
BioMarin Pharmaceutical Inc. |
(415) 455-7558 |
(628) 269-7393 |
SOURCE BioMarin Pharmaceutical Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。